Genelux (GNLX) Non Operating Income (2022 - 2026)
Genelux (GNLX) recorded quarterly Non Operating Income of $243000.0 in Q1 2026, up 47.27% quarter-over-quarter from $165000.0 in Q4 2025, and down 25.0% on a YoY basis from $324000.0 in Q1 2025.
Genelux (GNLX) Non Operating Income (2022 - 2026) Analysis & Trends
Genelux's Non Operating Income history runs 5 years deep, the most recent figure standing at $243000.0 for Q1 2026.
- In Q1 2026, Non Operating Income fell 25.0% year-over-year to $243000.0; the TTM figure through Mar 2026 stood at $988000.0 (down 47.61% YoY), while the FY2025 annual figure was $1.1 million, down 41.49% from the prior year.
- Non Operating Income was $243000.0 for Q1 2026 at Genelux, up from $165000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $772000.0 in Q4 2024 to a low of -$3.9 million in Q1 2023.
- Historically, Non Operating Income has averaged -$115266.7 across 5 years, with a median of $243000.0 in 2026.
- The sharpest annual moves came in 2024 and 2025: Non Operating Income jumped 1347.37% in 2024, then plunged 78.63% in 2025.
- A 5-year view of Non Operating Income shows it stood at -$401000.0 in 2022, then soared by 158.35% to $234000.0 in 2023, then surged by 229.91% to $772000.0 in 2024, then slumped by 78.63% to $165000.0 in 2025, then jumped by 47.27% to $243000.0 in 2026.
- The last three Non Operating Income figures came in at $243000.0 (Q1 2026), $165000.0 (Q4 2025), and $244000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | 243,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 243,000.00 |
| Dec 31, 2025 | 165,000.00 |
| Sep 30, 2025 | 244,000.00 |
| Jun 30, 2025 | 336,000.00 |
| Mar 31, 2025 | 324,000.00 |
| Dec 31, 2024 | 772,000.00 |
| Sep 30, 2024 | 474,000.00 |
| Jun 30, 2024 | 316,000.00 |
| Mar 31, 2024 | 265,000.00 |
| Dec 31, 2023 | 234,000.00 |
| Sep 30, 2023 | -38,000.00 |
| Jun 30, 2023 | -426,000.00 |
| Mar 31, 2023 | -3.90 Mn |
| Dec 31, 2022 | -401,000.00 |
| Sep 30, 2022 | -335,000.00 |